Psychiatr. pro Praxi, 2005; 6: 278-281 [Interní Med. 2005; 7(9): 401-404]

Modern pharmacotherapy for insomnia

doc. MUDr. Karel Šonka CSc1, prof. MUDr. Soňa Nevšímalová DrSc2
1 Centrum pro poruchy spánku a bdění, Neurologická klinika 1. LF UK a VFN, Praha
2 Neurologická klinika 1. LF UK a VFN, Praha

Insomnia is a most frequent disease. Chronic insomnia is carefully studied in terms of etiology, and, in terms of therapy, classified as secondary if it is concomitant to some other disease, in which case treatment is directed toward the latter, and as primary insomnia. Pharmacotherapy for insomnia is represented mainly by hypnotics (benzodiazepines and hypnotics of the 3rd generation), and by some sedatively acting antidepressants. An overview is presented of some currently applied medicinal products designed to control the condition.

Keywords: Key words: insomnia, hypnotics, benzodiazepines, antidepressants.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šonka K, Nevšímalová S. Modern pharmacotherapy for insomnia. Psychiatr. praxi. 2005;9(6):278-281.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Billiard M, ed. Sleep: physiology, investigations and medicine. New York: Kluver Academic/Plenum Publisher, 2003; 1-764. Go to original source...
    2. Chaudhuri RK, Odin P, Olanov CW, ed. Restless legs syndrome. London: Taylor and Francis, 2004; 1-147. Go to original source...
    3. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000; 15: 141-152. Go to original source... Go to PubMed...
    4. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, Šonka K, Unden M: Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Internat Clin Psychopharmacol 2002; 17: 9-17. Go to original source... Go to PubMed...
    5. Idzikowski C, Mills FJ, Glennard R. 5-hydroxytryptamine-2 antagonist increases human slow vawe sleep. Brain Research 1986; 378: 164-168. Go to original source... Go to PubMed...
    6. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301-310. Go to original source... Go to PubMed...
    7. Kryger MH, Roth T, Dement WC ed. Principles and practice of sleep medicine. 4th edition. Philadelphia: Elsevier Saunders, 2005; 1-1517.
    8. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26: 793-799. Go to original source... Go to PubMed...
    9. Mathias S, Wetter TC, Steiger A, Lancel M. The GABA uptake inhibitor tiagabine promotes slow wawe sleep in normal elderly subjects. Neurobiol Aging 2001; 22: 247-253. Go to original source... Go to PubMed...
    10. Mathias S, Zihl J, Steiger A, Lancel M. Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Neuropsychopharmacology 2005; 30: 833-841. Go to original source... Go to PubMed...
    11. Morin CM, Hauri PJ, Espie CA, Speilman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. Sleep 1999; 22: 1134-1156. Go to original source... Go to PubMed...
    12. Nevšímalová S, Šonka K, ed. Poruchy spánku a bdění. Praha: Maxdorf, 1997; 1-255.
    13. Richardson G, Doghramji K. Insomnia: Specialist´s edition. Clinical Symposia 2005; 55: 3-39.
    14. Šonka K. Hypnotika. Remedia 2003; 13: 437-441. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.